Connor, Clark & Lunn Investment Management (CC&L)
PRQR icon

Connor, Clark & Lunn Investment Management (CC&L)’s ProQR Therapeutics PRQR Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-69,973
Closed -$560K – 1175
2021
Q4 		$560K Buy
69,973
+31,614
+82% +$241K ﹤0.01% 779
2021
Q3 		$321K Buy
+38,359
New +$251K ﹤0.01% 860

Other funds holding PRQR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PRQR Position: Q1 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of ProQR Therapeutics (PRQR) in Q1 2022, closing a stake of 69,973 shares — an estimated $560K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PRQR in Q3 2021 and held it in 2 quarters. The position peaked at $560K in Q4 2021. 58 funds tracked by Wall St. Rank hold PRQR as of Q1 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining ProQR Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 69,973 ProQR Therapeutics shares in Q1 2022, an estimated $560K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ProQR Therapeutics in Q3 2021 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s ProQR Therapeutics position peaked at $560K in Q4 2021.
  • 58 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2022, filed 12 May 2022.